The brief

Analyst view

• YB002 is a brain injection plus oral pill to reverse neurodegeneration at the epigenetic level.
• FDA confirmed preclinical data and trial plan in September 2025 INTERACT meeting.
• Manufacturing optimization and toxicology studies underway; first-in-human trials expected 2028–2029.

Technical approach

As reported

Mechanism

Transient OSKM reprogramming

Transiently activates Oct4, Sox2, Klf4, c-Myc factors for limited time to reverse epigenetic aging.

Delivery

Brain injection plus pill

Gene therapy injected into the brain; oral pill activates reprogramming, then stops it.

Target

Alzheimer's neurodegeneration

Reverses brain cell aging markers linked to Alzheimer's, restoring youthful gene expression.